Abstract
Introduction

49
Protein-based therapeutics enable targeted approaches for treating cancer (1). There are many 
Methods
83
EgKI-1 expression in yeast 84 The pPICZαA plasmid containing the EgKI-1 gene sequence and EcoRI/ XbaI cloning sites 85 was synthesized by Biomatik (Wilmington, USA). The plasmid (10 ng) was then transformed 86 into E. coli XL1-Blue competent cells (Stratagene, San Diego, USA) and sequenced to 87 confirm the integrity of the insertion. Vector bearing the confirmed sequence was inserted 88 into Pichia pastoris KM71H cells using the electroporation method described by 89 Invitrogen TM (Carlsbad, USA). Briefly, a single colony of XL1-Blue cells, bearing the 90 confirmed EgKI-1 sequence isolated from a low salt LB agar plate, was grown in 5 ml of low 91 salt LB medium. From these cells, DNA was extracted using a Plasmid Midi kit (Qiagen,
92
Hilden, Germany). DNA was linearized with SacI-HF (New England BioLabs, Ipswich, 93 USA), extracted using phenol/chloroform and re-suspended in 10 mM Tris (pH 8.5) buffer.
94
Linearized DNA (25 µg) was then mixed with 80 µl KM71H cells on ice and transferred to a 95 0.2 cm cuvette and an electric shock applied using Gene Pulser (Biorad, Hercules, USA). 
Protein purification and identification
110
The cultured supernatant (200 ml) was then collected by centrifugation at 10,000 rpm for 30 111 min at 4 o C and stored at -80 0 C until required. The supernatant was thawed, dialyzed into 50 112 mM MES buffer (pH 6) and filtered through a 0.45 µm filter before being loaded on to a Hi-113 trap SP sepharose column (GE Healthcare Life Sciences) pre-equilibrated with 50 mM MES 114 buffer (pH 6) (18). Unbound material was removed by washing with equilibration buffer and 115 protein was eluted using a linear gradient of 0-1 M NaCl over 40 ml, with EgKI-1 eluting 116 between 0.4 and 0.6 M NaCl. Purification was monitored by analysis on SDS-PAGE gels and 117 protease inhibitory activity in fractions containing EgKI-1. Purified EgKI-1 was then 118 dialyzed into 50 mM Tris 120 mM NaCl (pH 7) buffer and quantified using the Bradford 119 protein assay (19). A sample of the EgKI-1 protein was visualized on 15% SDS-PAGE to 120 verify its purity and the EgKI-1 gel band was subjected to in-gel trypsin digestion and nano 
158
The distance between one side of scratch and the other at each time point was measured using 24-well plates and EgKI-1 or control buffer treatment was carried out on the following day.
196
After 24 hours incubation, cells were harvested by trypsinisation and washed with cold PBS. 
Results
287
Recombinant EgKI-1 expression and purification 288 In order to examine the effects of EgKI-1 on cancer cell lines the protein was expressed in Real time monitoring using the IncuCyte showed that cells treated with 1 µM EgKI-1 303 eventually lost their typical shape, lost their ability to proliferate with time (Fig 1a) , and 304 exhibited dose-dependent growth inhibition compared with the control cells (Fig 1b) .
305
Furthermore, the IncuCyte analysis showed that cells continued to grow in the presence of 306 EgKI-1, at a concentration of around 0.5 µM, before starting to die after ~60 hours making it 307 a more sensitive assay than end point staining. and 100% in the controls respectively (Fig 2b) . This data indicates that EgKI-1 inhibits 319 cancer cell migration. which can lead to cell membrane collapse and eventually necrosis. There were significant 325 decreases in the intensity of tubulin and total cell area indicating the degradation of the 326 cytoskeleton following treatment with the EgKI-1 protein (Fig 3) . (Fig 4) . In HeLa cells, When injected intraperitoneally into mice, the EgKI-1 protein was absorbed into the blood in (Fig 6) . Furthermore, expression of Ki67 protein, which is a 366 proliferation marker, was significantly reduced in the EgKI-1-treated tumor tissues indicating 367~80% reduction of tumor proliferation (Fig 6) as suggested by the in vitro data. EgKI-1 is also an important aspect to consider for cancer therapeutic development.
383
Further, the apparent cell growth inhibition by EgKI-1 was due to an increase in apoptosis, 
